Skip to search boxSkip to navigationSkip to main content

An update of ALK inhibitors in human clinical trials

*Corresponding author for this work
  • The University of Hong Kong
Scholary Output:
Contribution to journal
Review article
Research
Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

<p>The proto-oncogenic ALK is a druggable receptor tyrosine kinase for cancer treatment. Two small molecule inhibitors of ALK, crizotinib and ceritinib, have been recently approved for the treatment of metastatic non-small-cell lung cancer, with marked improvement of progression-free survival of patients. Independent case reports also indicate their potential therapeutic activity in other ALK-rearranged cancers. Numerous single-agent and combination therapy trials are ongoing in lung and many other cancers. Results of these trials are greatly anticipated. Here, we summarize our current understanding of ALK signaling, genomic aberrations in cancer and emerging mechanisms of drug resistance. We will also provide a timely review on all ALK inhibitors and their current status of development in clinical settings.</p>

Publication Information

Output type

Scholary Output:
Contribution to journal
Review article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 71-81 (11 pages)

Journal (Volume, Issue Number)

Future Oncology (Volume 12, Issue 1)

Publication milestones

  • Published - 01/2016

Publication status

Published - 01/2016

ISSN

1479-6694

Publication IDs

  • Scopus: 84952066272
  • PubMed: 26618223

Publication metrics

Metrics

Fractional count
1
Fractional count
0.33
Fractional count
2
Fractional count
0.67
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Citation count
10
Captures
19